Damora Therapeutics, Inc.
Damora Therapeutics develops biologics for mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis.
10-QAug 10Latest SEC filing, period to Jun 30
Jul 20Latest story
July 2026